Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation Jun 23, 2009
Grants will support areas of study in pediatric lupus and adult stem cell transplantation. The purposes of the studies are to advance adult stem cell transplantation research in humans as a treatment for lupus and address key understanding of pediatric/adolescent lupus research issues ... While stem cell transplantations are currently being tested and explored in clinics and labs, researchers are only beginning to understand the potential impact and role of adult stem cells in the development... (PR Newswire)
Donor Stem Cell Transplantation Associated With Survival Benefit For Patients With Leukemia Jun 19, 2009
ScienceDaily (June 19, 2009) An analysis of previous studies indicates that allogeneic stem cell transplantation (SCT) (stem cells from a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia in first complete remission, compared with nonallogeneic SCT therapies, according to a new article ... Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First... (Science Daily)
5 Spanish centers join a study for a new leukemia and lymphoma treatment technique Jun 4, 2009
It is estimated that more than 11,000 patients in the European Union are in need of an allogeneic (from a source outside of the patient's body) hematopoietic (blood) stem cell transplantation. This is an unofficial figure calculated based on the method proposed by the US government's General Accounting Office (GAO) report and The EBMT Activity Survey 2006 on Hematopoietic Stem Cell Transplantation: Focus on the Use of Cord Blood Products ... The company is developing a pipeline of products in... (EurekAlert! -- Business News)
New therapy enlists immune system to boost cure rate in a childhood cancer May 28, 2009
Half received the immunotherapy, while half received standard therapy (chemotherapy and stem cell transplantation). The patients who received the immunotherapy were 20 percent more likely than those in the standard therapy group to live disease-free two years after treatment. (EurekAlert!)
New Tool Against Deadly Childhood Cancer May 15, 2009
Although barely a toddler, Brian received aggressive therapy: chemotherapy, surgery, radiation and stem cell transplantation. But then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell. (CBS News)
Association of IL-10 and IL-10R beta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor May 4, 2009
Extensive allelic matching in the human leukocyte antigen (HLA) genes is regarded as a prerequisite for good clinical success of allogeneic haematopoietic stem cell transplantation (HSCT). Also other genetic factors can be assumed to play a role in preventing and controlling the complications associated with allogeneic HSCT, in particular graft-versus-host disease (GvHD). (BioMed Central)
Simple formula: Raise money & find a cure Apr 16, 2009
Muzaffar Qazibash, M.D., an associate professor in M.D. Anderson s Department of Stem Cell Transplantation and Cellular Therapy, has developed a vaccine for patients with recurring Acute Myeloid Leukemia (AML). Trials for the vaccine began in 2000. (Alpine Avalanche, TX)
Stem Cell Transplantation Helps Patients With Diabetes Become Insulin Free Apr 16, 2009
15, 2009) The majority of patients with type 1 diabetes who underwent a certain type of stem cell transplantation became insulin free, several for more than three years, with good glycemic control, and also increased C-peptide levels, an indirect measure of beta-cell function, according to a new study ... Clinical evidence indicates that there is an inverse association between beta-cell (a type of cell in the pancreas that secretes insulin) preservation and function and chronic complications of... (Science Daily)
Type 2 diabetics more susceptible to dementia Apr 15, 2009
In another study, Richard Burt of Northwestern University Feinberg School of Medicine in Chicago presented research in which 23 patients with type 1 diabetes underwent a certain type of stem cell transplantation. Twenty were able to temporarily go off insulin for extended periods that ranged from 14 to 52 months. (USA Today)
Nature Reviews Nephrology (formerly Nature Clinical Practice Nephrology) Mar 27, 2009
Fofi and colleagues describe a rare case of focal segmental glomerulosclerosis occurring as a complication of chronic graft-versus-host disease following peripheral blood stem cell transplantation. Current Issue. (Nature News Service)
Bone Marrow Transplantation Feb 8, 2009
Volume 43, No 2January (2) 2009ISSN: 0268-3369EISSN: 1476-5365. 2007 impact factor 3. (Nature News Service)
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma Mar 18, 2008
Standard treatments include anticancer drugs, steroids, stem cell transplantation, and radiation therapy. The overall five-year survival rate is 34. (Primezone Releases)
New Target For Cancer Therapy May Improve Treatment For Solid Tumors Mar 6, 2008
22, 2008) It is possible to cure some individuals with leukemia by infusing them with immune cells known as lymphocytes during a surgical procedure known as hematopoietic stem cell transplantation (HCT). (Nov. (Science Daily)
Immune System Versus Solid Tumor: An Example Of The Immune System Winning Feb 22, 2008
22, 2008) It is possible to cure some individuals with leukemia by infusing them with immune cells known as lymphocytes during a surgical procedure known as hematopoietic stem cell transplantation (HCT) ... Journal reference: Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. (Science Daily)
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes Feb 16, 2008
Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. (PR Newswire)
Researcher gets seat on cord blood bank board Feb 6, 2008
has named Dr. John Wagner, a prominent researcher in the field of cord blood stem cell transplantation, to its five-member scientific advisory board. Orlando based- CORD:USE is working to create a large, ethnically diverse inventory of cord blood stem cells which is used in the treatment of more than 70 blood cancers and diseases. (Orlando Business Journal)
Kidney Cancer Drug Attacks A Major Type Of Acute Myeloid Leukemia Feb 2, 2008
D., professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy and Department of Leukemia ... D., all of the department of Stem Cell Transplantation and Cellular Therapy; David Harris, Zeev Estrov, M.D., and Alfonso Quintas-Cardama, M.D. all of the Department of Leukemia; and David Small, M.D. of Johns Hopkins University School of Medicine. (Science Daily)
FDA Approves Additional Indication for Astellas' MYCAMINE(R) Jan 23, 2008
MYCAMINE was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation ... MYCAMINE is approved for the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses; for the treatment of patients with Esophageal Candidiasis and the prophylaxis of Candida Infections in patients undergoing... (PR Newswire)
Methylgene and Pharmion Start Phase II Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Jan 9, 2008
Lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation are usually B-cell NHLs. Currently, there is no known cause of the disease, but epigenetic alterations including histone acetylation, have been identified. (CCNMatthews Press Releases)
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma Dec 10, 2007
- VELCADE, thalidomide and dexamethasone improved pre - and post-stem cell transplantation results compared to thalidomide and dexamethasone - ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: ) reported the presentation of results from an interim analysis of the first 256 patients evaluated in a multi-center, randomized Phase III clinical trial ... "These exciting results demonstrated that adding VELCADE to the standard induction therapy prior to stem cell... (PR Newswire)
Vaccine improves event-free survival for leukemia patients Dec 10, 2007
"We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival" says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy ... The PRI vaccine was developed by Jeffrey Molldrem, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation ... D., Shreya Kant, Sergio Giralt, M.D., Krishna Komanduri, M.D., and Richard... (EurekAlert!)
Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS) Dec 10, 2007
Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00 p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center Session: Clinical Care: Transplantation Regimen Toxicities and Engraftment II -- Poster Board No. 231-III: A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS (Abstract #3012). -- Poster Board No. 232-III: Efficacy of Azacytidine... (PR Newswire)
Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 Dec 10, 2007
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C306- C308, Georgia World Congress Center Session: Autologous Transplantation for Myeloma: Induction, Mobilization, and Biologic Correlates -- Oral Presentation - 2:00 p.m.: Incorporation of Thalidomide into Up- Front Double Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma Improves Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predictive of Outcome (Abstract #447). (PR Newswire)
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy Dec 10, 2007
These patients with previously untreated multiple myeloma (MM) were ineligible for stem cell transplantation (SCT) ... "Data from this rigorously-controlled trial clearly show that VELCADE based therapy should be a standard of care for previously untreated patients, who are not able to receive stem cell transplantation." Data from the large international clinical trial were presented by Professor San-Miguel. (PR Newswire)
Hana Biosciences Presents Marqibo Data At the 49th Annual Meeting of the American Society of Hematology Dec 9, 2007
Five responders were able to undergo allogeneic stem cell transplantation following therapy with Marqibo. The maximum-tolerated dose was established in the Phase 1 trial as 2. (Primezone Releases)
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH Nov 24, 2007
In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH. ATIR: presentation of clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy Title poster: "Phase I/II clinical trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte Infusions depleted of Alloreactive Cells using ATIR may improve outcome without causing GvHD - Abstract #2976; Poster 2976, Board #195-III (10 December,5-7 pm) Dr. Denis... (PR Newswire)
Lung-on-a-chip Leads To New Insights On Pulmonary Diseases Nov 20, 2007
1, 2003) For the first time, researchers have demonstrated that adult human stem cell transplantation results in spontaneous cell regeneration in damaged lung tissue. Published in the August 1 issue of the. (Science Daily)
Don't Tell Mother She Has Cancer? Nov 3, 2007
14, 2005) In the first study of its kind, researchers say half of patients undergoing stem cell transplantation exhibit signs of delirium, but the warning signs are subtler and can be easily missed by. . (Science Daily)
Recent Increase In Multiple Myeloma Survival Attributed To Novel Therapies Nov 3, 2007
Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic interventions such as stem cell transplantation, according to the results of two studies prepublished online in Blood ... Also, over the past decade high-dose chemotherapy and peripheral blood stem cell transplantation has been increasingly used for treatment of MM, especially in younger patients ... Study results illustrated a dramatic improvement in survival among patients diagnosed in... (Science Daily)
Studies attribute recent increase in multiple myeloma survival to novel therapies Nov 2, 2007
Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic interventions such as stem cell transplantation, according to the results of two studies prepublished online in Blood, the official journal of the American Society of Hematology ... Also, over the past decade high-dose chemotherapy and peripheral blood stem cell transplantation has been increasingly used for treatment of MM, especially in younger patients ... Study results illustrated a... (EurekAlert!)
Kiadis Pharma Announces ATIR Interim Clinical Results Oct 10, 2007
Successful Independent Clinical Evaluation of ATIR by Dr. Velardi for Mismatched Bone Marrow Transplantation AMSTERDAM, Netherlands, Oct. 10 /PRNewswire/ -- Kiadis Pharma today announced interim results of a physician initiated European Phase II clinical study for its lead product ATIR. Professor Velardi from the University of Perugia in Italy presented the successful treatment of thirteen end stage blood cancer patients with a mismatched bone marrow transplantation during the 5th workshop on... (PR Newswire)
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia Aug 22, 2007
According to the FDA, Marqibo is eligible for Fast Track designation because there is an unmet medical need in adult patients with Philadelphia chromosome negative ALL who have relapsed twice or who have failed two lines of anti-leukemia chemotherapy, including those who have undergone stem cell transplantation. Hana's Phase 2 clinical trial, known as the rALLy study, is a multi-center, multi-national trial evaluating Marqibo in this patient population. (Primezone Releases)
Stem cell transplantation procedure results in long-term survival for amyloidosis patients Aug 8, 2007
(Boston) Researchers from the Stem Cell Transplant Program and the Amyloid Treatment and Research Program at Boston University Medical Center (BUMC) have found that high-dose chemotherapy and blood stem cell transplantation can result in long-term survival for patients diagnosed with primary systemic light chain (AL) Amyloidosis ... The researchers reviewed the records of 80 patients who received high-dose chemotherapy and blood stem cell transplantation from July 1994 through July 1997 ...... (EurekAlert!)
Tekmira Partner Begins Phase 2 Clinical Trial for Marqibo(R) Aug 3, 2007
The patient population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation. In this trial Hana expects to enroll up to 56 patients. (CCNMatthews Press Releases)
Edward Boyse dies Aug 2, 2007
a University of Arizona researcher who first identified distinct subclasses of T-cells and also helped lay the foundation for umbilical cord stem cell transplantation, died July 14 of pneumonia. He was 83. (The Scientist)
June 18: Friends host drive to aid local woman with leukemia Jun 19, 2007
In the very small proportion of patients who are under 50 with a severe form of myelodysplastic syndrome, intensive radiation and/or chemotherapy followed by allogeneic stem cell transplantation can be considered (see Blood and Marrow Stem Cell Transplantation booklet) ... Younger individuals who are candidates for allogeneic stem cell transplantation may have restoration of normal blood cell formation after a successful transplant. (Westerly Sun, RI)
Opine: John Cunningham Jun 8, 2007
His observations in the laboratory and at the bedside-form a foundation for modern blood stem cell transplantation and other stem cell therapeutic technologies. In addition, he identified the source of erythropoietin, a hormone critical for patients with kidney failure and blood diseases. (Univeristy of Chicago Chronicle, IL)
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients Jun 4, 2007
TT3, a treatment for newly diagnosed multiple myeloma patients, includes a VELCADE based therapy prior to and as maintenance following stem cell transplantation ... Patients received two cycles of a combination called VTD-PACE (VELCADE, thalidomide, dexamethasone, cisplatin, adriamycin, cyclophosphamide and etoposide) as induction therapy prior to and as consolidation therapy following stem cell transplantation. (PR Newswire)
XOMA Reports First Quarter 2007 Results May 11, 2007
-- XOMA announced that it had initiated an open-label, dose-escalating Phase I/II clinical trial of NEUPREX(r) in adults and children undergoing stem cell transplantation at several Harvard Medical school clinics ... In January of 2007, in conjunction with Harvard Medical School, XOMA initiated a Phase I/II clinical trial of NEUPREX(r) in adults and children undergoing allogeneic hematopoietic stem cell transplantation (``HSCT'') to evaluate safety, pharmacokinetics and markers of biological... (Primezone Releases)
Intravenous Nanoparticle Gene Therapy Shows Activity In Stage IV Lung Cancer Apr 19, 2007
D., M. D. Anderson Department of Stem Cell Transplantation; Lin Ji, Ph. D., Rajagopal Ramesh, Ph. (Science Daily)
Treatment shows promise against diabetes Apr 11, 2007
The patient, who does not wish to have his name used, underwent autologous hematopoietic stem cell transplantation in March 2004 and has been off insulin since the 6th day after the stem cell infusion, according to Voltarelli ... The hazards of stem cell transplantation also raise questions about whether the study should have included children. (Seattle Post Intelligencer)
Treating Parkinson's disease Mar 25, 2007
Growden: A lot of the enthusiasts and advocacy groups in the Parkinson's community are keen on stem cell transplantation and are a little upset that there seems to be a limitation on research in that area. That certainly holds great promise, but there are many years to go. (CNN)
Paul Varghese of NBC's Last Comic Standing to Perform at Improv Addison, Benefiting The Leukemia & Lymphoma Society Jan 26, 2007
Innovations in cancer treatment over the years have included radiation and chemotherapy, stem cell transplantation and new targeted therapies that kill cancer cells without harming normal cells. Source: The Leukemia & Lymphoma Society. (Yahoo! Wire -- Entertainment News)
Relationship Between Delirium And Dementia Jan 16, 2007
(January 14, 2005) -- In the first study of its kind, researchers say half of patients undergoing stem cell transplantation exhibit signs of delirium, but the warning signs are subtler and can be easily missed by. . (Science Daily)
